10-K · April 1, 2026
Synergy CHC positions itself as an asset-light nutraceutical brand platform focused on two marquee brands (FOCUSfactor and Flat Tummy) and plans to accelerate FOCUSfactor RTD and geographic expansion. Financially the…
Earnings analysis · 10-Q
SNYR earnings analysis
Filed May 14, 2026 · Our reading of the company's report
The latest report
Synergy CHC Corp. reported disappointing results for Q1 2026, with revenues declining to $5.49M, a decrease of approximately 33% from $8.17M in Q1 2025. The company's net loss widened to $2.57M, compared to a gain of…
Read full summary
Synergy CHC Corp. reported disappointing results for Q1 2026, with revenues declining to $5.49M, a decrease of approximately 33% from $8.17M in Q1 2025. The company's net loss widened to $2.57M, compared to a gain of $0.88M in the same quarter last year, reflecting deteriorating performance and challenges in their product sales.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.35
- Gross margin
- 72%
What stood out
-
Significant Revenue Decline
Revenue fell to $5,492,705 in Q1 2026, down from $8,170,534 in Q1 2025, representing a decrease of 33%.
-
Widening Net Loss
Net loss reached $2,568,899 in Q1 2026, a shift from a net income of $876,264 in Q1 2025.
-
Gross Margin Decline
Gross profit margin decreased to 72% in Q1 2026, down from 75% in Q1 2025.
-
Increased Operating Expenses
General and administrative expenses rose to $2,048,850 in Q1 2026, compared to $1,306,714 in Q1 2025.
-
High Interest Expense
Interest expense increased to $2,012,121 in Q1 2026 from $1,095,369 in Q1 2025.
-
Cash Position Weakening
Cash on hand decreased to $292,115 as of March 31, 2026, raising liquidity concerns.
What to watch
-
Substantial Accumulated Deficit
Accumulated deficit grew to $59,009,920 by Q1 2026, reflecting ongoing financial struggles.
-
Liquidity Concerns
The company reported a working capital deficit of $503,862, indicating potential liquidity issues.
-
Decreasing Consumer Demand
A notable decrease in online sales contributed to the revenue drop in Nutraceuticals, questioning future performance.
Management's outlook
Outlook deferred to earnings press release / call.
Earlier filings 4
10-K · March 31, 2025
The 2024 Form 10-K positions Synergy CHC around two core brands (FOCUSfactor and Flat Tummy) with an asset-light, retailer-focused growth strategy driven by SKU expansion, RTD pilots and international entry plans…
10-Q · December 6, 2024
Synergy CHC Corp. reported Q3 2024 revenues of $7.13 million, down 34% from $10.81 million in Q3 2023 and year-to-date revenues of $24.56 million, down 17% year-on-year. The company reported net income of $783,593 this…
10-Q · November 14, 2019
Synergy CHC reported quarter revenues of $7,364,546 (down from $9,190,377 a year ago) while recording net income of $107,864 for the three months and year-to-date net income of $1,893,613 versus a loss of $(493,296)…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.